The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - foundation me
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Foundation Medicine; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer
 
Adanma Ayanambakkam
No Relationships to Disclose
 
Syed Mohammad Ali Kazmi
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Abhishek Tripathi
Consulting or Advisory Role - AADi; Bayer; Deka Biosciences; Exelixis; Gilead Sciences; Seattle Genetics/Astellas
Speakers' Bureau - Sanofi
Research Funding - Aravive (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst)
 
Aurelien Marabelle
Stock and Other Ownership Interests - Adagene; Centessa Pharmaceuticals; Deka Biosciences; HiFiBiO Therapeutics; HotSpot Therapeutics; Marengo Therapeutics; Shattuck Labs
Honoraria - ESMO; European Journal of Cancer; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Adagene; Alderaan Biotechnology; Andera; Asgard Therapeutics; Atreca; BiolineRx; Centessa Pharmaceuticals; Clover Biopharmaceuticals; Daiichi Sankyo Europe GmbH; Deka Biosciences; Depth Charge Therapeutics; Grey Wolf Therapeutics; Gritstone Bio; Guidepoint Global; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MSD; Neogene Therapeutics; Pathios Therapeutics; Pegaone; Pierre Fabre; Redx Pharma; Sanofi; Shattuck Labs; Sotio; Takeda; Tegus
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - HiFiBiO Therapeutics; Marengo Therapeutics; Pathios Therapeutics; Sotio
Other Relationship - Elsevier
 
Allison Long
Employment - Deka Biosciences
Stock and Other Ownership Interests - Deka Biosciences
 
Debra A. Kientop
Employment - Deka Biosciences
Stock and Other Ownership Interests - Deka Biosciences
 
Stanley R. Frankel
Employment - Cytovia Therapeutics
Leadership - Myeloid Therapeutics; Precision Biosciences
Stock and Other Ownership Interests - Adagene; Precision Biosciences; Sutro Biopharma
Honoraria - Chimeric Therapeutics; OPKO Health
Consulting or Advisory Role - Adagene; AstraZeneca; Autolus Therapeutics; Cargo Therapeutics; Deka Bioscience; Harpoon therapeutics; Immunai; Myeloid Therapeutics; Precision Biosciences; Sutro Biopharma
 
John Mumm
Employment - Deka Biosciences
Leadership - Deka Biosciences
Stock and Other Ownership Interests - Deka Biosciences
Research Funding - Deka Biosciences
Patents, Royalties, Other Intellectual Property - I am an author on multiple patents regarding use of cytokines in the treatment of cancer and inflammatory diseases.
Travel, Accommodations, Expenses - Deka Biosciences
 
Douglas W. Orr
Stock and Other Ownership Interests - Avalo Therapeutics